SAA1 knockdown promotes the apoptosis of glioblastoma cells via downregulation of AKT signaling

Huikai Zhang1,2, Yang Xu1,2, Gang Deng1,2, Fanen Yuan1,2, Yinqiu Tan1,2, Lun Gao1,2, Qian Sun1,2, Yangzhi Qi1,2, Kun Yang1,2, Rongxin Geng1,2, Hongxiang Jiang1,2, Baohui Liu1,2, Qianxue Chen1,2

1. Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China. 2. Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, China.

Corresponding authors: Qianxue Chen, Email: chenqx666@whu.edu.cn; Baohui Liu, Email: bliu666@whu.edu.cn. Postal address: No.238, Jiefang Road, Wuchang District, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Province, China.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2020.05.19; Accepted: 2021.02.18; Published: 2021.03.10

Abstract

Serum amyloid A1 (SAA1) is an inflammatory associated high-density lipoprotein. And it is also considered as a predictor and prognostic marker of cancer risk. However, its role and mechanisms in glioblastoma (GBM) still unclear. In this study, we validate that SAA1 is up-regulated in GBM, and its high expression predicts poor prognosis. SAA1 knockdown promotes the apoptosis of GBM cell. Mechanistically, SAA1 knockdown can inhibit serine/threonine protein kinase B (AKT) phosphorylation, thereby regulating the expression of apoptosis-related proteins such as Bcl2 and Bax, leading to GBM cell death. Moreover, Gliomas with low SAA1 expression have increased sensitivity to Temozolomide (TMZ). Low SAA1 expression segregated glioma patients who were treated with Temozolomide (TMZ) or with high MGMT promoter methylation into survival groups in TCGA and CGGA dataset. Our study strongly suggested that SAA1 was a regulator of cells apoptosis and acted not only as a prognostic marker but also a novel biomarker of sensitivity of glioma to TMZ.

Key words: Serum amyloid A1; Glioblastoma; Apoptosis; AKT; Temozolomide.

Introduction

Glioma is the malignant tumor with the highest incidence in the central nervous system. Its incidence is second only to meningiomas, accounting for about 40% to 60% of intracranial tumors [1]. Among gliomas, glioblastomas account for the highest proportion. Gliomas usually show a high degree of cleavage, necrosis, and aggressiveness [2]. At present, most glioma treatment methods are surgical treatment, and then decide whether to perform radiochemotherapy according to the tumor pathological grade and molecular diagnosis of the patient [3]. However, due to the high invasiveness of the tumor, it is difficult to completely remove. Despite aggressive surgical and routine treatment, the average survival time of patients after diagnosis is only 12-15 months [4]. At present, more and more molecular biology studies on gliomas have given scholars a deeper understanding of the pathogenesis of such tumors. Gene therapy has gradually become a research hotspot, and search for biomarkers that can detect early, diagnose early, and monitor prognosis and recurrence is a priority.

SAA1 is a sensitive acute phase high-density lipoprotein, which is mainly produced by the liver as a response to the body's acute inflammatory and tissue damage. It is generally used to evaluate the course of acute phase reactions. SAA1 may participate in the body’s immune system, promote the repair of damaged tissues, and be used as a diagnostic or prognostic marker for many diseases [5, 6]. In recent years, the role of SAA1 in the occurrence and development of tumors has received increasing attention. It is considered as a predictor and prognostic marker of tumor risk [7, 8]. It plays a significant role in the malignant progression and prognosis of many tumors. In patients with prostate cancer, gastric cancer, lung cancer, breast cancer, endometrial cancer, esophageal cancer and melanoma, the high expression of serum SAA1 levels have been shown to be associated with poor survival.
Inflammation, cell proliferation and angiogenesis. SAA1 participates in a molecular network that connects the inflammation, cell proliferation and angiogenesis. SAA1 in GBM are still unclear, previous research has found that astrocytoma patients (AGII to AGIV/GBM) have increased levels of serum SAA and that depletion of SAA1 could induce GBM cell apoptosis. Mechanistically, SAA1 knockdown can inhibit AKT phosphorylation, thereby inhibiting Bcl2 and promoting Bax expression, leading to GBM cell death. Meanwhile, the expression level of SAA1 may be related to the sensibility to TMZ in GBM patients.

Materials and methods

Bioinformatics

To clarify the expression and prognostic role of SAA1 in gliomas, we used the Gene Expression Omnibus (GEO) dataset (https://www.ncbi.nlm.nih.gov/gds/), Gliovis database(http://gliovis.bioinfo.cnio.es/) and the UCSC Xena platform (http://xena.ucsc.edu/). GSE52009 was downloaded from the GEO; the data about mRNA expression, survival analysis and Pearson correlation analysis were from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) database which downloaded in the Gliovis. Specific information on postoperative treatments (chemo/radiotherapy) of glioma patients was downloaded from UCSC Xena platform. Making analysis about biological mechanism related to SAA1 expression by Gene set enrichment analysis (GSEA).

Clinical tissue samples

Glioma tissues were obtained from the department of neurosurgery in Renmin hospital of Wuhan University, Wuhan, China. None patients received any chemo-or radiotherapy before surgery. Non-glioma tissues were collected from patients with severe traumatic brain injury during surgery and their families. All patients signed informed consents and this study received the approval of the Ethics Committee of Renmin Hospital of Wuhan University (approved number: 2012LKSZ (010) H).

Immunohistochemical staining

The paraformaldehyde-fixed paraffin tissue microarray that contained 140 glioma tissues was used. The microarray was incubated with a primary anti-SAA1 monoclonal antibody (YN3036, immunoway, USA) overnight at 4°C. Images were captured using an Olympus BX40 microscope (Tokyo, Japan). The result was primarily based on the strength of staining and the number of positive cells. 10 high magnification fields were randomly selected for observation.

ELISA assay

The ELISA kit (HM10751, Bio-Swamp, China) assay Human SAA1 level in the sample, used purified Human SAA1 antibody to coat microtiter plate wells,
made solid-phase antibody, then added SAA1 to wells. Combined SAA1 antibody with HRP labeled, became antibody-antigen-enzyme-antibody complex, added TMB substrate solution, TMB substrate became blue color at HRP enzyme-catalyzed, reaction was terminated by the addition of a sulphuric acid solution and the color change was measured at a wavelength of 450 nm. The concentration of SAA1 in the samples was then determined by comparing the O.D. of the samples to the standard curve.

**Antibodies and drugs**

The antibodies included the following: anti-SAA1 (YN3036, immunoway, USA), anti-GAPDH (#5174, Cell signaling Technology(CST), USA), anti-Bcl-2 (127891, Proteintech, USA), anti-Bax (50599-2, Proteintech), anti-Phospho-AKT(#4060, CST), anti-AKT (#4691, CST), anti-cleaved-caspase3 (ab32042, Abcam, UK), anti-caspase3 (19677-1-AP, Proteintech). AKT activator SC79 was purchased from Sellect (S786303, purity (>97%), USA) and dissolved in dimethyl sulfoxide (DMSO), which was obtained from Servicebio (G5051, Wuhan, China).

**siRNA transfection**

siRNA that specific targeting human SAA1 mRNA (SiSAA1-1, SiSAA1-2) and negative control SiRNA (SiNC) were obtained from Ribobio Corporation (Guangzhou, China). Transfection was done using X-tremeGENE siRNA transfection reagent (Roche, Germany) according to the manufacturer’s protocol. The sequences included the following:

- **SiSAA1-1**: GCGATGCCAGAGAGAATAT (Target sequence)
- **SiSAA1-2**: CTGGCCTGCCTGAGAAATA (Target sequence)

**Cells, cell culture and transfection**

U251 and U87 which are two human glioblastoma-derived cancer lines, were purchased from the Cell Bank Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). Cell lines were all cultured at 37°C under a humidified atmosphere of 5% CO2 by using Dulbecco’s modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Gibco, Invitrogen, Carlsbad, CA, USA). SC79 was used at 10 µM.

**Flow cytometric analysis**

Annexin V-PE/7-AAD kit (Becton Dickinson, USA) were used to measure the apoptosis of glioma cells. As request of the manufacturer’s instruction, Cells were digested and collected, washed for 3 times, stained with Annexin VPE/7-AAD for 10 min in the dark. Apoptosis was analyzed by FACS Calibur flow cytometer (Becton Dickinson). PE Annexin V and 7-AAD negative indicate viable; PE Annexin V positive and 7-AAD negative indicate early apoptosis; PE Annexin V and 7-AAD positive indicate late apoptosis or dead. Early apoptosis and late apoptosis were summed and the total apoptosis rate was calculated.

**Mitochondrial membrane potential (ΔΨm) assay**

JC-1 fluorescent probe (Yeasen, Shanghai, China) was used to detect the change of ΔΨm. Images were obtained by Olympus BX51 microscope (Olympus, Japan). The change of ΔΨm was reflected by the change of fluorescence color caused by the change of JC-1 morphology from aggregates to monomers.

**Western blotting**

U251 and U87 were lysed in a modified RIPA buffer (Beyotime, Shanghai, China) on ice for about 30 minutes, then centrifuged at 12,000rpm for 15 minutes. For frozen glioma tissues, we added 1ml of RIPA lysate per 100mg of tissues. The concentration of the sample was quantitatively determined by BCA protein assay. The lysate was mixed with loading buffer after heated at 100°C for 5mins. The proteins were separated at 10%-15% SDS-PAGE colloid and then transferred to the PVDF membrane (Millipore, Germany). Next PVDF membrane was seal with 5% non-fat milk for 1.5 hour and incubated with primary antibody at 4°C overnight. Secondary antibodies (Antgene, Wuhan, China,1:10000) were used to incubate the membrane in shade environment at room temperature for 1h. The membranes were visualized with Odyssey (LI-COR biosciences, USA). The above show primary antibodies. Western blot analysis was repeated three times.

**Cell count kit-8(CCK8) assay**

CCK8 assay, 3,000 glioma cells were resuspended in DMEM supplemented with 10% FBS and then added to a 96 well plate. Various concentrations of TMZ were added. Cell proliferation was investigated using CCK8 (Dojindo Molecular Technologies, USA) according to the manufacturer’s instruction.

**TUNEL assay**

In Fluorescein (FITC) Tunel cell apoptosis detection Kit (G1501, Servicebio, China) was used to detected DNA fragmentation in apoptotic cells according to the manufacturer's instruction. Only in apoptotic cells can there be green fluorescence localized by FITC-12-dUTP. Olympus BX51 microscope (Olympus, Japan) was used for image acquisition.
Statistical analysis

Data were presented as mean values ± standard deviation (SD) from at least three experiments. Student’s t-test was used to analyze the differences between two groups. Patients were divided into high and low groups according to the 50% cutoff point of SAA1 expression and Kaplan–Meier survival analysis was used to analyzed significance between groups. Pearson test was used for analyzing the correlation between SAA1 and other genes. Statistical analyses were performed using GraphPad Prism 8.0 software. A p value of less than 0.05 was considered as statistical significance.

Results

SAA1 is upregulated in human GBM and predicts poor prognosis

We first performed differential expressed gene analysis based on 96 low-grade glioma samples and 24 GBM samples in the GSE52009 database, which visualize as a heat map (Fig. 1A). The expression of SAA1 in GBM is significantly higher than that of low-grade gliomas (logFC=2.06, p<0.0001). This result is also verified in the public TCGA and CGGA databases (Fig. 1B). And SAA1 was highly expressed in IDH wild-type patients (Fig. 1C). Moreover, SAA1 protein level was also elevated in HGG compared with that of LGG detected by IHC staining and WB (Figure 1D-1F). ELISA detected the concentration of SAA1 protein in the serum of 7 healthy or traumatic brain injury (TBI) subjects and 11 glioma patients. In the serum of patients with glioma, SAA1 levels are increased (Fig. 1G, p<0.01). Then we performed survival analysis according to data from TCGA database. The results indicate that patients with high SAA1 expression, regardless of low-grade gliomas or GBM, have a poor prognosis (Fig. 1H). These results verified that SAA1 was upregulated in GBM and predicted poor prognosis.

SAA1 knockdown induces GBM cell apoptosis in vitro

To investigate the role of SAA1 in GBM, we performed loss of function study on U251 and U87 cells. Different SiRNAs that specific target SAA1 (SiSAA1-1 and SiSAA1-2) were synthesized and their knock-down effects were verified by western blot (first band in Fig. 2D). Firstly, we performed JC-1 staining to evaluate cell death. The decrease of mitochondrial membrane potential (ΔΨm) is a marker of early apoptosis, we found that SAA1 knockdown induced the loss of ΔΨm in GBM cells (Fig. 2A). And the flow cytometry analysis of annexin PE / 7-AAD staining showed that SAA1 knockdown induced apoptosis in U87 and U251 cells (Fig. 2C). In addition, we found that in glioma tissues from the TCGA database, SAA1 levels were associated with a range of anti-apoptotic genes (Bcl-xl, BFL1, MCL1, BIRC5, and Fas) and pro-apoptotic genes (Bim, Bid, CASP9 and Apaf1) (Fig. 2B). To increase persuasion, we examined the expression of apoptosis-related proteins. Western blotting showed that SAA1 knockdown increased Bax and cleaved-caspase3 levels, decreased Bcl-2 levels, and total caspase3 levels remain almost unchanged (Fig. 2D). We found the expression level of SAA1 affected the apoptosis of glioma cells.

SAA1 knockdown inhibits AKT phosphorylation

Previous studies have found that many cytokines may activate AKT signaling pathways to effect phosphorylation of bcl-2 family members, thereby inhibit apoptosis and promote cell survival. Poor phosphorylation of AKT in vitro and in vivo blocks poorly induced primary neuronal death. Then we examine the expression levels of AKT, p-AKT and AKT pathway downstream apoptosis-related proteins. Our results revealed that SAA1 knockdown may promote apoptosis by decreasing p-AKT levels. Then, we used the AKT phosphorylation activator SC79 to perform cell experiments to eliminate the effect of SAA1 knockdown. The annexin PE/7-AAD and JC-1 staining results showed that after SC79 activator was added, the rate of apoptotic cells in U87 and U251 cells decreased then before, which was still higher than normal cells (Fig. 3A, B, D). Western Blot showed SC79 activator eliminates the effects of SAA1 down-regulation on the expression levels of BCl2, Bax and cleaved-caspase3 to varying degrees (Fig. 3C). At the same time, we found that AKT phosphorylation activator promoted the expression of SAA1, which indicated that there may be positive feedback regulation of SAA1 and AKT pathway.

There is no specific discussion on how SAA1 affects AKT phosphorylation, we conducted a GSEA study using glioma patient gene profiling data (GSE52009), and as shown (Fig. 3E), gene set differences in high versus low expression of SAA1 in GBM patients indicated that SAA1 may regulate biology process associated with cytokine-cytokine receptor interaction (p<0.01, ES=0.52), ECM-receptor interaction (p<0.01, ES=0.59), Focal adhesion (p<0.01, ES=0.41) and Jak-STAT signaling pathway (p<0.01, ES=0.42). SAA1 may affect the AKT pathway activation by affecting the above processes, or directly affect the AKT phosphorylation process, and further research is needed.
**SAA1 knockdown enhances the sensitivity of glioma cells to TMZ**

We used the CCK-8 assay to detect the survival rate of U87 and U251 cells treated with different concentrations of TMZ and the results showed that inhibition of SAA1 enhanced the efficacy of TMZ and decreased cell survival rate (Fig. 4A, B). The results of annexin PE/7-AAD revealed that SAA1 knockdown significantly increased GBM cells apoptosis caused by TMZ treatment, and AKT phosphorylation activator SC79 weaken the effects of SAA1 down-regulation (Fig. 4C, D). Our findings were verified by TUNEL assay and we found rate of TUNEL positive cells in SiSAA1 groups was much higher than that of SiNC group (Fig. 4E, F). These results strongly indicated that the down-regulation of SAA1 enhanced sensitivity to TMZ chemotherapy in GBM and might be a promising target. Taken together, we demonstrated that SAA1 knockdown promoted GBM cells apoptosis by regulating AKT signaling, which enhanced sensitivity to TMZ.
SAA1 is a novel biomarker of response to TMZ in glioma

We found that SAA1 was highly expressed in IDH wild-type patients, and considering the relationship between IDH type and TMZ resistance, we tried to investigate whether SAA1 could be used as a biomarker of TMZ therapeutic-response. We analyzed the effect of SAA1 expression on the survival time of glioma patients with different treatments by using public TCGA and CGGA datasets. We found that GBM patients with low SAA1 expression survived significantly longer than those with high expression if they were treated with TMZ at any time, and the patients who were treated with ionizing radiation (IR) alone, SAA1 expression had no significant effect on survival time (Fig. 5A). Consistent with this finding, in LGG patients with high SAA1 expression had shorter survival time than those expressed low SAA1 if they treated with TMZ at any time, whereas SAA1 expression wasn’t significantly associated with survival time of patients who were treated with IR alone (Fig. 5B).

In addition, MGMT methylation status and 1p/19q codeletion are often used to evaluate the sensitivity of patients to chemotherapy and radiation therapy in clinical. Then we further analyze whether SAA1 plays a role in it. First, patients with methylated MGMT promoter and 1p/19q codeletion had lower SAA1 expression levels than those with unmethylated MGMT promoter and 1p/19q non-codeletion (Fig. 5E, F). These results showed that SAA1 might be a crucial gene involved in chemoresistance of glioma to TMZ. Besides, in the GBM and LGG patients with methylated MGMT promoter, the lower the expression of SAA1, the longer the overall survival time. In LGG patients with unmethylated MGMT promoter, the same results were found, but there was no significant difference in GBM patients (Fig. 5C).
And patients with 1p/19q codeletion with low SAA1 expression had better prognosis, SAA1 expression had no significant effect on survival of 1p/19q non-codeletion GBM patients (Fig. 5D). Our data showed that patients with methylated MGMT promoter or 1p/19q codeletion who had high SAA1 expression presented similar prognosis with patients with unmethylated MGMT promoter or 1p/19q non-codeletion. Taken together, these results suggested that SAA1 was a novel biomarker in predicting TMZ response in glioma patients.
Figure 4. SAA1 knockdown enhances the sensitivity of glioma cells to TMZ. (A, B) CCK-8 assay was used to detect the survival rate of U87 and U251 cells treated with different concentrations of TMZ, and different times with certain TMZ concentrations (400 μM); (C, D) U87 and U251 cells treated with certain TMZ concentrations (400 μM). The apoptosis cells were detected by flow cytometry; (E-F) Representative images of TUNEL staining. Scale bars, 50 μm.

Discussion

SAA1 is the precursor protein of inflammation-related amyloidosis. After different degrees of injury, infection, inflammation and new tumors occur in the body, its serum level will rapidly increase by more than 1000 times [30]. High levels of SAA1 are associated with chronic inflammatory diseases, including atherosclerosis, rheumatoid arthritis and Alzheimer’s disease (AD) [31]. In brain diseases, study [32] has found that the abnormal expression of SAA in the AD brain may directly participate in the occurrence or continuation of the AD process. At the same time, more and more attention has been paid to the role of SAA1 in the occurrence and development of tumors. It is considered as a predictor of cancer risk and a prognostic marker, and plays an important role in the malignant development and prognosis of many tumors.

Previous studies have found that SAA1 is highly expressed in GBM [22]. We verified the high expression of SAA1 in GBM through various databases such as GEO, TCGA, CGGA and clinical samples, and found that it predicts a poor prognosis. In this study, we found that SAA1 was upregulated in GBM and that SAA1 depletion induced GBM cell apoptosis in vitro. Mechanism studies reveal that SAA1 knockdown inhibits AKT phosphorylation to regulate expression of apoptosis-related proteins downstream of the AKT signaling pathway, induce apoptosis. AKT phosphorylation activator can significantly relieve the effect of SAA1 knockdown. At the same time, our results found that the down-regulation of SAA1 enhanced sensitivity to TMZ chemotherapy in GBM, and SAA1 was closely related to IDH type, MGMT promoter methylation status and 1p / 19q co-deletion status. SAA1 may was a novel biomarker in predicting TMZ response in glioma patients.
High levels of SAA1 are thought to be the cause of organ damage in diseases such as systemic amyloidosis and Alzheimer's disease. Studies have found that SAA has not only been shown to induce lysis of bacterial cells by forming ion channels in lipid bilayer membranes [33], but also to prevent cell death from eukaryotic cells [34, 35]. Previous research has focused on the role of SAA1 in the transformation of malignant tumors, cell proliferation and anti-angiogenesis in uterine, lung, and nasopharyngeal carcinomas, and invasion and metastasis in gliomas [16, 17, 19, 22]. Study [36] has found that the combination of SAA1 and integrin αvβ3 is involved in the occurrence and progression of glioma disease. Adhesion receptor integrin αvβ3 is considered to be a sign of angiogenesis, which initiates calcium-dependent signaling pathways, leads to endothelial cell migration, and plays an important role in vascular...
cell biology [37]. SAA1 may regulate the proliferation and migration of endothelial cells induced by glioma by binding to integrin αvβ3, thereby promoting tumor angiogenesis. However, little is known about the effect of SAA1 on cell apoptosis in GBM. Our results show that SAA1 knockdown induces GBM cell apoptosis in vitro.

AKT plays a central role in the coordination of multiple signal transduction processes involved in transcriptional regulation, cell survival, and apoptosis. The main mechanism of AKT activation is the binding of ligands to cell membrane receptors. These ligands include growth factors such as insulin-like growth factor 1 (IGF-1) and platelet-derived growth factor (PDGF), cytokines, hormones, and mitogens [28, 38]. Recently, it has been demonstrated that SAA may elicit cytokine and chemokine production and cell migration [39, 40]. On the molecular level, SAA has been shown to stimulate several proinflammatory and anti-apoptotic signaling pathways including NF-KB, C/EBP, JNK, ERK, AKT and p38 to stimulate tissue remodeling and wound healing [41-43]. Our study demonstrated that SAA1 may regulate GBM cells apoptosis by activating AKT signal pathway. We found that GBM cells reduced AKT phosphorylation after down-regulating SAA1 expression and increased apoptosis. The knockdown of SAA1 caused changes in the expression of BCL2 family proteins and apoptotic proteins such as Bax, Bim and Bid, as evidenced by Western blotting and high-throughput data analysis. In order to prove that the apoptosis of GBM cells caused by SAA1 knockdown is related to the decrease of AKT phosphorylation, we used AKT phosphorylation activator SC79 to eliminate the phosphorylation changes caused by SAA1 knockdown. Our results showed that SC79 significantly reduced GBM cell apoptosis after SAA1 knockdown. At the same time, we found that the expression of SAA1 increased to a certain extent after the increase of AKT phosphorylation. The specific mechanism is not clear. We speculate that there may be a positive-feedback regulation mechanism.

How SAA1 affects AKT phosphorylation is the direction of our next research. Some current studies may make conjectures. Studies have found that phosphoinositide 3-kinase (PI3K) recruits AKT to the plasma membrane to cause conformational changes, resulting in Thr308 site of AKT phosphorylated by phosphoinositide kinase 1 (PDK1) and Ser473 site phosphorylated by rapamycin complex 2 (mTORC2) [44, 45]. In addition to mTORC2, there are many different kinases, such as dna-dependent protein kinase (DNA-PK), which is responsible for phosphorylation and activation of the Ser473 site of AKT [46]. Tumor suppressor phosphatase and tensin homologues (PTEN) and PH domain leucine-rich protein phosphatase (PHLPP) negatively regulate AKT through dephosphorylation [47]. In addition, GSEA results showed that SAA1 was likely to regulate biology process in GBM associated with cytokine-cytokine receptor interaction, ECM-receptor interaction, Focal adhesion and Jak-STAT signaling pathway. These signaling pathways are involved in cell adhesion, migration, proliferation, and apoptosis. SAA1 affects AKT phosphorylation through these pathways or other ways, and SAA1 may participate in more biological processes of GBM cells. There are vast research prospects here.

Besides its pivotal role in normal cellular physiology, many studies have demonstrated the activation of AKT cascade in various types of human cancer that often results in tumor aggressiveness and drug resistance [48]. We found that the down-regulation of SAA1 enhanced sensitivity to TMZ chemotherapy in GBM. We used TCGA and CGGA datasets to analyze whether SAA1 expression affected survival of glioma patients who treated with different treatments. Our results demonstrated that SAA1 segregate both LGG and GBM patients into survival groups if they were treated TMZ at any time, which gave us a hint that SAA1 might be related to TMZ resistance. MGMT methylation level and 1p/19q codeletion is an important indicator to predict the effect of TMZ-chemotherapy. Our data showed that in patients with methylated MGMT and 1p/19q codeletion who had high SAA1 expression presented similar prognosis with patients with unmethylated MGMT or 1p/19q non-codeletion. Among those patients, patients with methylated MGMT or 1p/19q codeletion that also had low SAA1 expression had best prognosis. These results indicated that SAA1 may was a novel biomarker of response to TMZ in glioma. In summary, SAA1 may affect GBM cell apoptosis by regulating AKT phosphorylation. Down-regulation of SAA1 can inhibit AKT phosphorylation to affect downstream signaling proteins, cause GBM cell apoptosis. At the same time, SAA1 may be related to TMZ sensitivity. Hence, SAA1 might be a potential therapeutic target and prognostic factor for treating GBM.

**Abbreviations**

SAA1: Serum amyloid A1; GBM: glioblastoma; AKT: serine/threonine protein kinase B; TMZ: Temozolomide; FPRL1: formyl peptide receptor-like-1; NO: nitric oxide; MMPs: metalloproteinases; BAD: bcl-2 cell death antagonist; GEO: Gene Expression Omnibus; TCGA: The Cancer Genome Atlas; CGGA: Chinese Glioma Genome Atlas; GSEA:
Gene set enrichment analysis; CST: Cell signaling Technology; IGF-1: insulin-like growth factor 1; PDGF: platelet-derived growth factor; PI3K: phosphoinositide 3-kinase; PDK1: phosphoinositide kinase 1; mTORC2: rapamycin complex 2; DNA-PK: dna-dependent protein kinase; PTEN: phosphatase and tensin homologues; PHLPP: PH domain leucine-rich protein phosphatase; AD: Alzheimer’s disease.

Acknowledgements

Availability of data and material

The data used to support the findings of this study are available from the corresponding author upon request.

Funding

This work was supported by the National Natural Science Foundation of China (No. 81572489, 81372683, and 81502175).

Author contributions

Huikai Zhang designed research. Huikai Zhang, Yang Xu, Gang Deng, and Fan’en Yuan carried out the experimental work. Yinqiu Tan, Lun Gao, Qian Sun, Yangzhi Qi, Kun Yang, Rongxin Geng, Hongxiang Jiang analyzed the data and wrote the paper. All authors read and approved the final manuscript.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Li R, Chen X, You Y, Wang X, Liu Y, Hu Q, et al. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics. Oncotarget. 2015; 6: 30968-74.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114: 97-109.
3. Eyupoglu IV, Buchfelder M, Savaskan NE. Surgical resection of malignant gliomas-role in optimizing patient outcome. Nat Rev Neurol. 2013; 9: 141-51.
4. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359: 492-507.
5. Yamada T, Okuda Y, Takasegi K, Wang L, Marks D, Benson MD, et al. An allele of serum amyloid A1 associated with amyloidosis in both Japanese and Caucasians. Amyloid. 2003; 10: 7-11.
6. Xie X, Ma YT, Yang YN, Li XM, Zheng YY, Liu F, et al. Genetic polymorphisms are associated with variation in antiangiogenic and tumor-suppressive activities in nasopharyngeal carcinoma. Oncogene. 2015; 34: 878-89.
7. Lee HY, Kim MK, Park KS, Bae YH, Yun J, Park JL, et al. Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocyte/macrophages. Biochem Biophys Res Commun. 2005; 330: 989-98.
8. Mullan RH, Bresnihan B, Golden-Mason L, Markham T, O’Hara R, FitzGerald O, et al. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappad-dependent signal transduction pathway. Arthritis Rheum. 2006; 54: 105-14.
9. Knebel FH, Uno M, Galarro TF, Belle LP, Oba-Shirino SM, Marie SKN, et al. Serum amyloid A1 is upregulated in human glioblastoma. J Neurooncol. 2017; 132: 383-91.
10. Knebel FH, Albuquerque RC, Massaro RR, Maria-Engler SS, Campa A. Dual effect of serum amyloid A on the invasiveness of glioma cells. Mediators Inflamm. 2013; 2013: 509809.
11. Manning BD, Toker A. AKT/PKB Signaling: Navigating the Network. Cell. 2013; 169: 381-405.
12. Sharati M, Meric-Bernstam F. Targeting AKT for cancer therapy. Expert Opin Investig Drugs. 2019; 28: 977-88.
13. Wang J, Zhao W, Guo H, Yang Y, Stockman SE, Bai S, et al. AKT isoform-specific expression and activation across cancer lineages. BMC Cancer. 2018; 18: 742.
14. Hanauda M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT—a major therapeutic target. Biochem Biophys Acta. 2004; 1697: 3-16.
15. Liao Y, Hung MC. Physiological regulation of Akt activity and stability. Am J Physiol. 2010; 2: 19-42.
16. Easton RM, Cho H, Roovers K, Shimenan DW, Mizrahi M, Forman MS, et al. Role for Akt3-protein kinase Bgammna in attainment of normal brain size. Mol Cell Biol. 2005; 25: 1699-79.
17. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999; 265: 501-23.
18. Uriel-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol. 2000; 7: 64-9.
19. Liang JS, Snowe JA, Wells JM, Abraham CR, Fine RE, Sipe JD. Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer’s disease brain. Neurosci Lett. 1997; 225: 73-6.
20. Pirukkaya R, Carreras I, Sipe JD, Kagan BL. Formation by serum amyloid A: a potential mechanism for amyloidogenesis and host defense. Amyloid. 2002; 9: 13-23.
21. Christensen K, Bjorkman L, Tannenbaum C, Bylund J. Serum amyloid A inhibits apoptosis of human neutrophils via a P2X7-sensitive pathway independent of formyl peptide receptor-like-1. J Leukoc Biol. 2008; 83: 139-48.
22. El Kebir D, Josset L, Khreis T, Pan W, Petasis NA, Serhan CN, et al. Aspirin-triggered lipoxins override the apoptosis-delaying action of serum amyloid A in human neutrophils: a novel mechanism for resolution of inflammation. J Immunol. 2007; 179: 616-22.
23. Lin CY, Yang SJ, Shen SC, Hsieh YC, Hsu FT, Chen CY, et al. Serum amyloid A1 in combination with integrin alphaVbeta3 increases glioblastoma cells mobility and progression. Mol Oncol. 2018; 12: 756-71.
24. Gaido KS, Clark RA, Cerecky JD. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994; 264: 569-71.
25. Scheid MP, Woodgett JR. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett. 2003; 546: 108-12.
26. Ye RD, Sun L. Emerging functions of serum amyloid A in inflammation. J Leukoc Biol. 2015; 98: 923-9.
27. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/Akt—a major therapeutic target. Biochem Biophys Acta. 2004; 1697: 3-16.
28. Liao Y, Hung MC. Physiological regulation of Akt activity and stability. Am J Physiol. 2010; 2: 19-42.
29. Easton RM, Cho H, Roovers K, Shimenan DW, Mizrahi M, Forman MS, et al. Role for Akt3-protein kinase Bgammna in attainment of normal brain size. Mol Cell Biol. 2005; 25: 1699-79.
30. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999; 265: 501-23.
31. Uriel-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol. 2000; 7: 64-9.
32. Liang JS, Snowe JA, Wells JM, Abraham CR, Fine RE, Sipe JD. Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer’s disease brain. Neurosci Lett. 1997; 225: 73-6.
33. Pirukkaya R, Carreras I, Sipe JD, Kagan BL. Formation by serum amyloid A: a potential mechanism for amyloidogenesis and host defense. Amyloid. 2002; 9: 13-23.
34. Christensen K, Bjorkman L, Tannenbaum C, Bylund J. Serum amyloid A inhibits apoptosis of human neutrophils via a P2X7-sensitive pathway independent of formyl peptide receptor-like-1. J Leukoc Biol. 2008; 83: 139-48.
35. El Kebir D, Josset L, Khreis T, Pan W, Petasis NA, Serhan CN, et al. Aspirin-triggered lipoxins override the apoptosis-delaying action of serum amyloid A in human neutrophils: a novel mechanism for resolution of inflammation. J Immunol. 2007; 179: 616-22.
36. Lin CY, Yang SJ, Shen SC, Hsieh YC, Hsu FT, Chen CY, et al. Serum amyloid A1 in combination with integrin alphaVbeta3 increases glioblastoma cells mobility and progression. Mol Oncol. 2018; 12: 756-71.
37. Gaido KS, Clark RA, Cerecky JD. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994; 264: 569-71.
38. Scheid MP, Woodgett JR. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett. 2003; 546: 108-12.
39. Ye RD, Sun L. Emerging functions of serum amyloid A in inflammation. J Leukoc Biol. 2015; 98: 923-9.
monocytes by activating a pertussis toxin-sensitive signaling pathway. J Immunol. 1995; 155: 4004-10.

41. Jijon HB, Madsen KL, Walker JW, Allard B, Jobin C. Serum amyloid A activates NF-kappaB and proinflammatory gene expression in human and murine intestinal epithelial cells. Eur J Immunol. 2005; 35: 718-26.

42. He R, Sang H, Ye RD. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPR1/LXA4R. Blood. 2003; 101: 1572-81.

43. Baranova IN, Vishnyakova TG, Bocharov AV, Kurlander R, Chen Z, Kimelman ML, et al. Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J Biol Chem. 2005; 280: 8031-40.

44. Conus NM, Hannan KM, Cristiano BE, Hemmings BA, Pearson RB. Direct identification of tyrosine 474 as a regulatory phosphorylation site for the Akt protein kinase. J Biol Chem. 2002; 277: 38021-8.

45. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/FKB by the rictor-mTOR complex. Science. 2005; 307: 1098-101.

46. Feng J, Park J, Cron P, Hess D, Hemmings BA. Identification of a PKB/Akt hydrophobic motif ser-473 kinase as DNA-dependent protein kinase. J Biol Chem. 2004; 279: 41189-96.

47. O’Neill AK, Niederst MJ, Newton AC. Suppression of survival signalling pathways by the phosphatase PHLPP. FEBS J. 2013; 280: 572-83.

48. Singh M, Johnson L. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin Cancer Res. 2006; 12: 5312-28.